These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 32275125)

  • 1. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
    Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
    Iaccarino L; Andreoli L; Bocci EB; Bortoluzzi A; Ceccarelli F; Conti F; De Angelis R; De Marchi G; De Vita S; Di Matteo A; Emmi G; Emmi L; Gatto M; Gerli R; Gerosa M; Govoni M; Larosa M; Meroni PL; Mosca M; Pazzola G; Reggia R; Saccon F; Salvarani C; Tani C; Zen M; Frigo AC; Tincani A; Doria A
    J Autoimmun; 2018 Jan; 86():1-8. PubMed ID: 28935492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
    Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
    Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
    Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
    Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
    Urowitz MB; Ohsfeldt RL; Wielage RC; Kelton KA; Asukai Y; Ramachandran S
    Ann Rheum Dis; 2019 Mar; 78(3):372-379. PubMed ID: 30610066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
    Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z; Zhang C; Gao C; Li C; Li R; Zheng Z
    Arthritis Res Ther; 2024 Sep; 26(1):163. PubMed ID: 39294688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.